Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00536497 |
GW842166X is a selective non-cannabinoid CB2 receptor agonist, which is undergoing clinical development as a novel oral treatment for inflammatory pain. The purpose of the study is to compare the effects of formulation, food and particle size on the pharmacokinetic profiles of a single 175mg dose of GW842166X in healthy male and female volunteers.
Condition | Intervention | Phase |
---|---|---|
Healthy Subjects |
Drug: GW842166X |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Crossover Assignment, Bio-availability Study |
Official Title: | A 2 Part Open-Label, Randomised, Crossover Study to Compare the Effects of Formulation, Food and Particle Size on the Pharmacokinetic Profiles of a Single 175mg Dose of GW842166X in Healthy Male and Female Volunteers |
Estimated Enrollment: | 36 |
Study Start Date: | September 2007 |
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | CBA109358 |
Study First Received: | September 25, 2007 |
Last Updated: | April 14, 2008 |
ClinicalTrials.gov Identifier: | NCT00536497 |
Health Authority: | United States: Food and Drug Administration |
GW842166, Healthy volunteers, Inflammatory Pain. |
Pain Healthy |